Patent controversies and court cases Cancer diagnosis, therapy and prevention

Cancer Biology and Therapy

Volumn 13, Issue 13, 2012, Pages 1229-1234

  Fialho, Arsenio M ^a   Chakrabarty, Ananda M ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Anticancer drugs; Breast ovarian cancer; Cancer diagnosis; Human genes mutations; Legal conflicts; Patents

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CIPROFLOXACIN; DNA; ERLOTINIB; IMATINIB; P28 PEPTIDE; PEPTIDE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG DOSE ESCALATION; DRUG INDUSTRY; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; KIDNEY CARCINOMA; LAW; LAW SUIT; LICENSING; LIVER CELL CARCINOMA; MEDICOLEGAL ASPECT; MELANOMA; MUTATIONAL ANALYSIS; PANCREAS CANCER; PATENT; PROSTATE CANCER; REVIEW; SARCOMA; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEGISLATION, DRUG; NEOPLASMS; PATENTS AS TOPIC;

EID: 84868368232     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21958     Document Type: Review

References (23)

1. Chakrabarty AM. Bioengineered bugs, drugs and contentious issues in patenting. Bioeng Bugs 2010; 1:2-8; PMID:21327122; http://dx.doi.org/10.4161/ bbug.1.1.9850.
2. Fialho AM, Chakrabarty AM. The role and importance of intellectual property generation and protection in drug development. In Fialho AM, Chakrabarty AM, eds. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools, Nutley: John Wiley & Sons, 2010: 405-19.
3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10. 1038/nature10166.
4. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330-7; PMID:22810696; http://dx.doi.org/10.1038/nature11252.
5. Fialho AM, Chakrabarty AM. Law-medicine interfacing: patenting of human genes and mutations. Recent Pat DNA Gene Seq 2011; 5:81-5; PMID:21574951; http://dx.doi.org/10.2174/187221511796392015.
6. Chakrabarty AM. Bacterial proteins: A new class of cancer therapeutics. J. Commercial Biotechnol 2012; 18:4-10.
7. Das Gupta TK, Chakrabarty AM, Beattie C, Yamada T. Compositions and methods to prevent cancer with cupredoxins. US Patent 8,232,244 issued on July 31, 2012.
8. Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, et al. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogeninduced mouse mammary lesions. Cancer Prev Res (Phila) 2010; 3:1351-60; PMID:20841487; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0024.
9. Richards JM, Warso MA, Mehta D, Christov K, Schaeffer CM, Yamada T, et al. A first-in-class, first-inhuman phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. J Clin Oncol 2011; 29: Abstract 2511 (ASCO Annual Meeting).
10. Fialho AM, Salunkhe P, Manna S, Mahali S, Chakrabarty AM. Glioblastoma multiforme: novel therapeutic approaches. ISRN Neurol 2012; 2012:642345; PMID:22462021.
11. Avner B, Fialho AM, Chakrabarty AM. Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework. Bioeng Bugs 2012; 3:262-7-8; PMID:22179143.
12. Resnik DB, DeVille KA. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro. Am J Bioeth 2002; 2:29-39; PMID:12230852; http://dx.doi.org/10.1162/152651602760250084.
13. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3-7; PMID:10619854; http://dx.doi.org/10.1172/JCI9083.
14. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009; 15:110-6; PMID:19122659; http://dx.doi.org/10.1038/nm.1863.
15. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signaling in a mouse model of lung adenocarcinoma. Nature 2009; 462:104-7; PMID:19847165; http://dx.doi.org/10.1038/nature08462.
16. Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 2011; 30:1812-21; PMID:21242979; http://dx.doi.org/10.1038/onc.2010.556.
17. Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry 2007; 46:1799-810; PMID:17249693; http://dx.doi.org/10.1021/bi061661x.
18. Micewicz ED, Jung C-L, Schaue D, Luong H, McBride WH, Ruchala P. Small azurin derived peptide targets ephrin receptors for radiotherapy. Int J Pept Res Ther 2011; 17:247-57; http://dx.doi.org/10.1007/s10989-011-9265-9.
19. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, et al. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc Natl Acad Sci U S A 2002; 99:14098-103; PMID:12393814; http://dx.doi.org/10.1073/pnas.222539699.
20. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004; 23:2367-78; PMID:14981543; http://dx.doi.org/10.1038/sj.onc.1207376.
21. Domenici F, Frasconi M, Mazzei F, D'Orazi G, Bizzarri AR, Cannistraro S. Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins. J Mol Recognit 2011; 24:707-14; PMID:21584881; http://dx.doi.org/10.1002/jmr.1105.
22. Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011; 14:355-69; PMID:21667138; http://dx.doi.org/10.1007/s10456-011-9220-6.
23. Zweig FM. The limiting factor. Biotechnology and the charter for an international science and technology reference court. Not Polit 2002; 18:51-8;PMID:15505917.